NasdaqGS - Delayed Quote USD

Autolus Therapeutics plc (AUTL)

4.0800 -0.1300 (-3.09%)
At close: April 25 at 4:00 PM EDT
3.9700 -0.11 (-2.70%)
After hours: April 25 at 4:11 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Christian Martin Itin Ph.D. CEO & Director 2.39M -- 1964
Dr. Martin Pule M.D., MBBS Founder, Senior VP & Chief Scientific Officer -- -- 1972
Mr. Robert F. Dolski Senior VP & CFO -- -- 1971
Mr. Christopher Vann Senior VP & COO -- -- 1965
Mr. David Brochu Senior VP & Chief Technical Officer -- -- 1956
Mr. Alexander Swan Senior VP & Chief Human Resources Officer -- -- 1965
Mr. Brent Rice Senior VP, Chief Commercial Officer & Site Head of US -- -- 1966
Ms. Olivia Manser Director of Investor Relations -- -- --
Mr. Alex Driggs Senior VP of Legal Affairs & General Counsel and Secretary -- -- --
Dr. Chris Williams Senior VP & Chief Business Development Officer -- -- 1980

Autolus Therapeutics plc

The Mediaworks
191 Wood Lane White City
London, W12 7FP
United Kingdom
44 20 3829 6230 https://www.autolus.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
463

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Corporate Governance

Autolus Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 14, 2024
Autolus Therapeutics plc Earnings Call

Related Tickers

ALLO Allogene Therapeutics, Inc.
2.8550
-6.09%
 
ADAP Adaptimmune Therapeutics plc
1.0600
-1.85%
 
FATE Fate Therapeutics, Inc.
3.8700
-10.00%
 
ARVN Arvinas, Inc.
31.60
-2.89%
 
TCRX TScan Therapeutics, Inc.
7.29
-1.22%
 
CTMX CytomX Therapeutics, Inc.
1.6000
-1.84%
 
IMCR Immunocore Holdings plc
58.00
-0.80%
 
SYRE Spyre Therapeutics, Inc.
32.47
-1.58%
 
AFMD Affimed N.V.
4.8800
0.00%
 
MRSN Mersana Therapeutics, Inc.
2.8500
-1.04%